Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Prostatic adenoma
ADR ID BADD_A03565
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.36      Reproductive neoplasms male benign
16.36.01      Prostatic neoplasms benign
16.36.01.001      Prostatic adenoma
21      Reproductive system and breast disorders
21.04      Prostatic disorders (excl infections and inflammations)
21.04.02      Prostatic neoplasms and hypertrophy
21.04.02.005      Prostatic adenoma
Description Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. | A disease caused by hyperplastic process of non-transformed prostatic cells. [MeSH]
MedDRA Code 10036940
MeSH ID D011470
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Prostate adenoma | Prostatic adenoma | Prostatic Hyperplasia | Hyperplasia, Prostatic | Prostatic Hypertrophy | Adenoma, Prostatic | Adenomas, Prostatic | Prostatic Adenomas | Prostatic Adenoma | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy, Benign | Benign Prostatic Hypertrophy | Hypertrophy, Benign Prostatic
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01817Pramipexole--
BADD_D01818Pramipexole dihydrochloride--
BADD_D01956Rivastigmine tartrate--
BADD_D02170Testosterone--
The 1th Page    1    Total 1 Pages